Abstract 392TiP
Background
Hypopharyngeal cancer is relatively rare, accounting for only 3% of head and neck cancers. A majority of the patients (pts) present at an advanced stage with a 5-year overall survival of 40%. Despite improvement in local regional control with neoadjuvant therapy, distant metastasis led to poor outcomes in hypopharyngeal cancer. Individualized adjuvant therapy based on pathologic complete response (pCR) and CD8+ T cell infiltration may be a promising strategy for pts after neoadjuvant therapy. Thus, we conducted a phase II study (ChiCTR2200055939) to evaluate the efficacy and safety of neoadjuvant and individualized adjuvant therapy and explore the correlation between tertiary lymphoid structures (TLS) and efficacy/immune microenvironment in pts with locally advanced hypopharyngeal cancer.
Trial design
In the prospective, open-label, single-arm phase II study, pts who have histologically or cytologically confirmed stage II-IVa hypopharyngeal cancer without recurrent/metastatic disease, ECOG performance status of 0-1, and predicted survival >3 months are eligible. Pts will intravenously receive 2-cycle neoadjuvant therapy with pembrolizumab (200 mg), albumin-bound paclitaxel (260 mg/m2), and cisplatin (100 mg/m2) on day 1 every 3 weeks. Surgical resection will be scheduled within 21-28 days after the final dose of neoadjuvant therapy. If postoperative pathology shows a pCR, pembrolizumab will be given as adjuvant therapy for 15 cycles. Pts with non-pCR but CD8+ cell density increased ≥20% from baseline will receive adjuvant radiotherapy (50-60Gy) plus pembrolizumab for 15 cycles; otherwise, non-pCR pts will withdraw from the study and receive conventional concurrent chemoradiotherapy. The primary endpoint is 12-month recurrence-free survival (RFS). Secondary endpoints are 18- and 24-month RFS, median RFS, pCR rate, and safety. Exploratory endpoints include the correlation between TLS and pathological response/RFS/immune microenvironment (eg, CD8+ cells, B/T lymphocytes). The phase 2 trial is ongoing.
Clinical trial identification
ChiCTR220005593p.
Legal entity responsible for the study
The Sixth Medical Center of Chinese PLA General Hospital.
Funding
Wu Jieping Medical Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract